US-based 3D-printed orthopaedic implants provider restor3d has raised $104m from Swiss private markets firm Partners Group and existing shareholders.
Partners Group will make a $65m new equity investment to acquire a significant minority stake, representing restor3d’s initial institutional investment.
Existing shareholders will invest $39m in the company to support its growth.
Restor3d intends to use the investment to advance product innovation, expand commercial growth, and improve access to personalised orthopaedic care.
Partners Group will join restor3d’s board of directors, providing operational experience and healthcare expertise to support its strategic goals.
Restor3d aims to develop a range of personalised orthopaedic solutions, enhancing digital surgical planning tools, and increasing its market presence.
Partners Group private equity management member Ashley Torres said: “restor3d is solving a key issue in the orthopaedic market, namely that procedures have often relied on off-the-shelf products that cannot accommodate different patient anatomies.
“Restor3d addresses this challenge by delivering rapid, precise patient-specific implants that lead to better surgical fit and function, ultimately improving patient outcomes.”
Private Equity Health & Life private equity health and life partner head Todd Miller said: “We think restor3d’s offering is set to benefit from several thematic trends, including ageing demographics and rising engagement in sports and recreational activities in the US. We look forward to working with the Company’s highly experienced management team.”
Founded in 2017, restor3d specialises in AI-driven design software and additive manufacturing for personalised orthopaedic implants.
The company offers the US Food and Drug Administration (FDA)-approved solutions for various joint replacements, including shoulder, hip, knee, foot, and ankle.
Last year, Restor3d collaborated with over 520 surgeons across 740 hospitals in the US, enhancing surgical fit and function with customised implants.
Restor3d CEO Kurt Jacobus said: “This investment marks an exciting milestone for restor3d as we expand access to personalised orthopaedic solutions.
“With Partners Group’s support, we will continue to deliver innovations that empower surgeons and improve outcomes for patients across the full spectrum of joint replacement.”
